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SARS-CoV-2 attacks various organs, most destructively the lung, and cellular entry requires
two host cell surface proteins: ACE2 and TMPRSS2. Downregulation of one or both of these
is thus a potential therapeutic approach for COVID-19. TMPRSS2 is a known target of the
androgen receptor, a ligand-activated transcription factor; androgen receptor activation
increases TMPRSS2 levels in various tissues, most notably prostate. We show here that
treatment with the antiandrogen enzalutamide—a well-tolerated drug widely used in
advanced prostate cancer—reduces TMPRSS2 levels in human lung cells and in mouse lung.
Importantly, antiandrogens significantly reduced SARS-CoV-2 entry and infection in lung
cells. In support of this experimental data, analysis of existing datasets shows striking co-
expression of AR and TMPRSS2, including in specific lung cell types targeted by SARS-CoV-2.
Together, the data presented provides strong evidence to support clinical trials to assess the
efficacy of antiandrogens as a treatment option for COVID-19.
https://doi.org/10.1038/s41467-021-24342-y OPEN
1 Department of Surgery and Cancer, Imperial College London, London, UK. 2 School of Life Sciences, University of Essex, Colchester, Essex, UK. 3 Department
of Infectious Diseases, Imperial College London, London, UK. 4National Heart and Lung Institute, Imperial College London, London, UK. 5These authors
contributed equally: C. L. Bevan, G. N. Brooke. ✉email: charlotte.bevan@imperial.ac.uk; gbrooke@essex.ac.uk









Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 pandemic, is a positive-sensesingle-stranded RNA coronavirus highly related to SARS-
CoV, which caused the 2002/2003 SARS pandemic1,2. Like SARS,
COVID-19 primarily affects the respiratory system (although other
organs can also be affected): symptoms are mild in some, but in
others the infection can result in pneumonia, acute respiratory
distress syndrome and death3. Risk factors associated with poor
prognosis include age, diabetes and cardiovascular disease4. It has
also been shown that gender is a prognostic factor, with approxi-
mately 60–70% of deaths being in men5,6, suggesting that sex
steroid hormones may be a contributing factor to the severity of
the disease. In further support of this, recent studies have shown
that men with male pattern hair loss (caused by elevated androgen
signalling7) are at higher risk of suffering more severe COVID-19
symptoms8,9.
Coronaviruses have structural (spike, nucleocapsid, membrane
and envelope) and non-structural (e.g., the proteases nsp3 and
nsp5) proteins10. Cellular entry of SARS-CoV-2 requires host
proteins expressed on the epithelial cell surface, most essential are
transmembrane serine protease 2 (TMPRSS2) and angiotensin-
converting enzyme 2 (ACE2)11–13. TMPRSS2 cleaves and primes
the viral Spike (or S) protein; this facilitates fusion of the viral
and host membranes14–18. Cellular entry is facilitated by
ACE2, a terminal carboxypeptidase and type I transmembrane
glycoprotein19. Thus, viral entry may be prevented or slowed by
inhibition of ACE2 and/or TMPRSS2. TMPRSS2 is an attractive
target as knockout of this protein causes no overt detrimental
phenotype20, whereas ACE2 downregulation is associated with
increased severity of SARS-induced lung injury21. Furthermore,
TMPRSS2 expression levels have been shown to be associated
with disease severity in mouse models of coronavirus infection22
and its inhibition was recently shown to inhibit SARS2-S-driven
entry in lung cells13.
Multiple studies have shown that TMPRSS2 is an androgen
receptor (AR) target gene in prostate cancer cells23–25. The AR
(NR3C4, nuclear receptor subfamily 3, group C, gene 4) is a
nuclear receptor and member of the steroid receptor family. It is a
transcription factor activated by binding of ligand (e.g., dihy-
drotestosterone (DHT)), upon which it translocates from the
cytoplasm to the nucleus where it binds to regulatory regions of
target genes as a homodimer. The active receptor then promotes
gene transcription, facilitated by pioneer factors (e.g., JUN and
FOXA1), and recruitment of accessory proteins and the basal
transcriptional machinery26. In the case of prostate cancer, active
AR promotes tumour growth and so treatment options for
prostate cancer often target this signalling axis, through the use of
androgen deprivation and hormonal therapies such as
antiandrogens27,28. Antiandrogens (e.g., bicalutamide (BIC) and
enzalutamide (ENZA)) interact with the AR in the ligand binding
pocket and hold the receptor in an inactive conformation, unable
to form an active transcriptional complex, and thus inhibit its
activity29. Importantly, previous studies have demonstrated that
the AR is expressed in the lung30 and studies using mice have
confirmed that AR is functional in this organ31,32. In corro-
boration, in vitro studies have shown that multiple lung lines
express functional AR31,33–35. It is therefore possible that inhi-
bition of androgen signalling, in response to antiandrogens, will
reduce TMPRSS2 expression in the lung and reduce viral entry.
For this reason, antiandrogens have been proposed as a treatment
option for COVID-1936–38.
Here we investigate AR regulation of TMPRSS2 in the mouse
lung and human lung cells. We show that TMPRSS2 is co-
expressed with the AR and that therapeutic antiandrogens
downregulate its expression in lung. Our analysis of steroid
receptor and cofactor enrichment upstream of TMPRSS2 suggests
that AR may promote gene expression in both lung and prostate
through distinct, cell-specific cistromic control. We show that
treating human lung cells with the antiandrogen ENZA reduces
entry and infection by the SARS-CoV-2 virus, providing pre-
clinical data to support the use of antiandrogens for the treatment
of COVID-19.
Results and discussion
TMPRSS2 is an androgen and antiandrogen-regulated gene.
ACE2 and TMPRSS2 are crucial for SARS-CoV-2 entry into
cells13, and hence these proteins represent potential therapeutic
targets for COVID-19. TMPRSS2 has been shown to be an AR
target gene in prostate cancer23–25 and we therefore hypothesised
that the expression of TMPRSS2 could be downregulated in
response to antiandrogens. To confirm this, the AR-positive
prostate cancer cell line LNCaP was seeded in hormone-depleted
media for 72 h and treated with DHT (10 nM) ± 10 μM of the
antiandrogens BIC or ENZA for 6 h. Alterations in gene
expression were quantified using qPCR. As expected, addition of
androgen significantly increased TMPRSS2 expression (Fig. 1a).
Importantly, the antiandrogens successfully blocked this
androgen-induced upregulation, resulting in significant inhibition
of TMPRSS2 expression. TMPRSS2 expression was also sig-
nificantly reduced by ENZA when cells were incubated in full
medium conditions (Supplementary Fig. 1a). To determine
whether AR regulation of TMPRSS2 also occurs in other cell
types, gene expression was investigated in the T47D breast cancer
cell line (GSE62243)39. In agreement with the LNCaP results,
TMPRSS2 was also found to be upregulated in response to DHT
in this line (Fig. 1b).
TMPRSS2 and the AR are co-expressed in the lung. Androgen
signalling is known to be important in multiple tissues/organs. To
better characterise this signalling, we previously created the AR-
LUC transgenic mouse in which luciferase expression is under the
control of an androgen-responsive promoter, allowing for visuali-
sation of both in vivo and ex vivo AR activity. AR signalling was
found to be active in a number of tissues/organs, including the
prostate, seminal vesicles, uterus and ovaries—and importantly,
AR signalling was also found to be active in the lungs of male and
female mice, although activity was weaker than in the reproductive
organs32. Other studies have also demonstrated that AR signalling is
active in the lung. For example, Mikkonen et al. found the AR to be
predominantly expressed in type II pneumocytes and the bronchial
epithelium, and microarray analysis of the murine lung demon-
strated that genes involved in oxygen transport (among other
pathways) are upregulated in murine lung tissue in response to
androgen31.
To investigate AR and TMPRSS2 expression in different
human tissues, we interrogated the Genotype Tissue Expression
(GTEx) dataset40. We found that AR and TMPRSS2 are co-
expressed in a number of tissues, and generally, TMPRSS2 is
only expressed in tissues that also show detectable levels of the
AR, with the exception of the pancreas (Fig. 2a). Importantly, AR
and TMPRSS2 were found to be co-expressed in the lung
(highlighted red, also highlighted are prostate, breast (both co-
expressing) and pancreas). Analysis of single-cell sequencing
data from lung tissue41 demonstrated that TMPRSS2, ACE2, AR
and AR-associated pioneer factors (JUN and FOXA1) are co-
expressed in Epithelial Subtype Ciliated and Alveolar Type 2
(AT2) cells (Fig. 2b). Similarly in a second single-cell dataset42,
AT2 cells were among the resident lung cells with the highest
expression of TMPRSS2, ACE2, and AR (Fig. 2c). These cell
types are targeted by SARS-CoV-243. These results are in
agreement with Qiao et al., who also found in analysis of
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published single-cell sequencing data that the AR, TMPRSS2 and
ACE2 are co-expressed in several human and mouse lung cell
types, most notably AT1 and AT2 cells, and ciliated and
secretory epithelial cells (bronchial cells)44.
TMPRSS2 expression in the lung is higher in men. In adults,
men have on average seven to eight times higher levels of cir-
culating testosterone compared to women45. Men are known to
have more severe symptoms following SARS-CoV-2 infection
(60–70% of COVID-19-related deaths are in men5,6) suggesting
elevated androgen signalling could be a risk factor for the disease.
Furthermore, recent studies have linked male pattern hair loss (a
result of elevated androgen signalling) with more severe COVID-
19 symptoms8,9. Since TMPRSS2 is an androgen-regulated gene,
it has been proposed that elevated levels of TMPRSS2 in the lung,
as a result of higher levels of androgen, might explain this gender
disparity and it was therefore hypothesised that TMPRSS2
expression would be higher in male lungs compared to females.
Our analysis of the GTEx dataset found no significant difference
in AR expression levels between men and women. TMPRSS2
expression was also found to be similar between males and
females (Fig. 3), but expression in the male lung was found to be
slightly and significantly higher, in agreement with a previous
study46. This is, however, in contrast to other studies that have
found no significant difference in TMPRSS2 expression in male
and female lungs37,47,48. Furthermore, Baratchian et al. found
higher levels of ACE2 in the male lung and proposed that
alterations in the levels of this receptor could, at least in part,
explain the gender disparity in COVID-19 severity47. It therefore
remains unclear if gender differences in TMPRSS2 expression
could explain why men suffer more severe symptoms following
infection with SARS-CoV-2.
TMPRSS2 expression is reduced by enzalutamide in lung cells.
As discussed above, the AR is expressed in human and murine
lung, and shown to be active as indicated by regulation of AR-
target genes in mouse lung31, nuclear localisation of AR in (male)
human lung31,49 and activation of an androgen-responsive
reporter gene in mouse lung32. TMPRSS2 expression has been
previously shown to be androgen-regulated in the A549 cell
line31. To replicate these findings, and to expand to other lung
lines, we seeded A549 (type II pneumocyte cell line; a cell type
targeted by SARS-CoV-243), H1944 (lung adenocarcinoma) and
BEAS-2B (bronchial epithelial) cells in hormone-depleted media
(containing serum that has been charcoal-stripped to remove any
traces of hormones) for 3 days, then treated with ±10 nM DHT ±
10 µM ENZA for 24 h (Fig. 4a). In A549 and H1944, addition of
DHT led to a significant increase in TMPRSS2 expression.
This induction was blocked following treatment with ENZA,
although this did not reach significance. ENZA treatment in full
media conditions also resulted in significant downregulation of
TMPRSS2 in A549 (Supplementary Fig. 1). Although DHT did
not induce TMPRSS2 expression in BEAS-2B, ENZA did appear
to reduce gene expression, suggesting that the AR could be
activating gene expression in a ligand independent manner in this
line. A similar trend was seen across the cell lines for another
known AR target gene, FKBP5; this was significantly upregulated
in response to DHT in A549 and H1944 and ENZA significantly
reduced this induction (Fig. 4b).
To confirm AR regulation of TMPRSS2 at the protein level,
A549 and H1944 cells were treated as above for 48 h (Fig. 4c)
before immunoblotting. DHT increased AR levels, and ENZA
prevented this ligand-mediated stabilisation of the receptor. In
agreement with the qPCR data, DHT increased TMPRSS2 protein
levels (approximately two-fold and five-fold, respectively) and
ENZA completely blocked this induction.
TMPRSS2 expression is reduced by enzalutamide in mouse
lung. To investigate the effects of ENZA on TMPRSS2 expression
in vivo, mice were treated for 3 days with ENZA or vehicle
control. Following sacrifice, lung tissue was collected and qPCR
performed to quantify alterations in gene expression. While there
was no significant change in Ar or Ace2 expression, Tmprss2
expression was significantly decreased after ENZA treatment (p
= 0.0367, Fig. 5a). Tmprss2 protein was found to be expressed in
the epithelial cells and in cells of the parenchyma, as suggested by
the single-cell sequencing data (Fig. 2), and intensity was visibly
less in mice treated with ENZA (examples in Fig. 5b). The Ar was
also found to be expressed in these cell types, with nuclear
localisation indicating active Ar, and ENZA treatment resulted in
a marked decrease in Ar levels in the lung (Supplementary Fig. 2).
To validate these findings, gene expression data from intact mice
Fig. 1 TMPRSS2 is an androgen-regulated gene in cells from different tissues. a LNCaP cells were incubated in hormone-depleted media for 72 h and
treated with ±10 nM dihydrotestosterone (DHT) ± 10 μM bicalutamide (BIC) or enzalutamide (ENZA) for 6 h. RNA was harvested, reverse transcribed and
qPCR performed to quantify TMPRSS2 expression. Mean of three independent repeats (±1 SEM). One-way ANOVA with Tukey’s multiple comparison test
**** Vehicle Control (VC) v DHT – p= 8.6 × 10–11, DHT v BIC – p= 4.9 × 10–11, DHT v DHT+ BIC – p= 7.3 × 10–10, DHT v ENZA – p= 4.0 × 10–11, DHT v
DHT+ ENZA – p= 1.0 × 10–10. b Data from T47D cells (GSE62243, N= 3)39 treated with 10 nM DHT were analysed for TMPRRS2 expression. One-tailed
t-test, *p= 0.0302. Source data are provided as a Source Data file.
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Fig. 2 TMPRSS2 and the AR are expressed in the lung. a The GTEx dataset40 was interrogated and median expression of AR was plotted against median
TMPRSS2 expression. Data are expressed as each gene normalised across all tissues (z-score). Highlighted are prostate (n= 245), lung (n= 578),
pancreas (n= 328) and breast (n= 459). b Single-cell analysis of lung tissue41 with each bar representing AR, TMPRSS2, ACE2, FOXA1, JUN expression
within individual cells of each specified cell type. c Single-cell analysis of lung tissue42 was interrogated and a breakdown is shown of AR, TMPRSS2 and
ACE2 expression levels in specific lung cell types (X-axis); Y-axis denotes gene mRNA CPM.
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and mice that had been castrated (removal of testicular produc-
tion of androgen) were interrogated (GSE31341)50. In agreement
with our cell line data, castration significantly reduced Tmprss2
expression in the mouse lung (Fig. 5c). In the same mice, cas-
tration was also associated with an increase in Ar expression (p=
0.0018), expected as Ar gene transcription is downregulated in
response to androgen51. In contrast to the results presented here,
Baratchian et al. found no regulation of Tmprss2 in the mouse
lung in response to ENZA47. However, in that study mice were
fed ENZA whereas in this study oral gavage was used. The
method of ENZA administration may therefore go some way to
explain this discrepancy.
Regulation of TMPRSS2 expression is tissue specific. Although
ChIP-Seq data for genomic AR binding in lung tissue or cells are
not available, we were able to assess the cistrome of FOXA1 and
JUN, known pioneer coregulatory factors for the AR52 and other
nuclear receptors. Binding of the glucocorticoid receptor (GR)
was also investigated as this can bind to many of the same
response elements as the AR53, also acetylated histone 27
(H3K27ac) as an indicator of active regulatory regions, all in
A549 lung cells (Fig. 6a). Binding profiles for prostate (LNCaP)
and breast (MCF-7) cell lines were included for comparison. In
LNCaP cells the AR binding pattern correlates with previous
findings24, and confirms that AR and GR bind in the same
regions, corresponding also to binding of the pioneer factor
FOXA1, and these sites largely correlate with the marker of
transcriptionally active regions, H3K27ac. Detailed analysis of
these potential response elements by the Claessens laboratory
demonstrated that an androgen response element in the enhancer
region (approximately –13 kb from the transcription start site) is
crucial for optimal androgen regulation of TMPRSS2 in prostate
cells24.
The binding patterns of GR, pioneer factors and H3K27ac in
lung cells, however, differ to what is seen in LNCaP cells (compare
regulatory region 1 and 2). To assess if androgen response elements
are present in regulatory region 2, the AR binding motif
(MA0007.2, Fig. 6b) from the JASPAR database was used to detect
AR target sites using methods previously described54. This analysis
identified potential androgen response elements throughout the 5’
region of the TMPRSS2 gene (Fig. 6a and Supplementary Table 1).
Importantly, several of the potential androgen response elements
were found to correlate with the GR, FOXA1, JUN, and H3K27ac
peaks seen in the A549 regulatory region 2. Together, this suggests
that AR (and associated factors) may directly regulate TMPRSS2 via
different regulatory regions in lung and prostate. To investigate this,
we performed ChIP-qPCR on these regions in LNCaP, A549 and
H1944 cells (Fig. 6c). In agreement with our prediction, the AR
binding sites differed between lines, with AR predominantly
binding to regulatory region 1 in LNCaP and regulatory region 2
in A549 and H1944. Li et al. also found AR binding upstream of
TMPRSS2 to differ between prostate and lung lines55. They
demonstrated AR binding to regulatory region 1 in LNCaP cells,
whereas the AR did not bind to this region in the lung cells
investigated, compatible with our analysis. However, that analysis
did not expand as far upstream as regulatory region 2, so did not
investigate whether the AR was present at regulatory region 2, as
demonstrated here. The data therefore suggest that the AR may
regulate TMPRSS2 expression differently in different tissues.
Further analysis will be required to confirm that AR binding to
these response elements regulates TMPRSS2 expression.
The DNA binding of AR, GR, FOXA1, JUN and H3K27ac
around the TMPRSS2 gene in breast cancer cells (MCF-7) appears
to be less pronounced than in prostate and lung, and the binding
pattern has elements of the binding patterns in both prostate and
lung cells. Importantly, AR binding in MCF-7 cells correlates with
the H3K27ac, FOXA1, JUN and GR peaks located distally in the
A549 regulatory region 2. Intriguingly, this region also correlates
with a peak for oestrogen receptor-α (ESR1) binding in MCF-7, and
oestrogen has been shown to downregulate TMPRSS2 expression56.
This supports the possibility of TMPRSS2 regulation by other
members of the nuclear receptor superfamily, and hence further
potential for pharmacological manipulation—in this case by oestro-
gens as well as, via the GR, glucocorticoids.
Antiandrogens can successfully reduce SARS-CoV-2 infection.
We have demonstrated that antiandrogens can successfully
reduce TMPRSS2 expression in lung cells. To test our hypothesis
that this will inhibit SARS-CoV-2 viral entry, A549 cells were
treated with BIC or ENZA for 72 h prior to transduction for 48 h
with SARS-CoV-2 Spike protein pseudotyped and luciferase-
expressing lentivirus (Fig. 7a). Both antiandrogens significantly
reduced viral entry, with the latter reducing cell entry by
approximately 50%. In contrast, cellular entry driven by the
glycoprotein of the pantropic vesicular stomatitis virus G protein
(VSV-G) was unaffected by the antiandrogens (Fig. 7a),
demonstrating that the effects of these drugs are specific for the
SARS-CoV-2 mechanism of cell entry. To confirm that ENZA
downregulates TMPRSS2 expression under these conditions (cells
grown in full media) at the point of viral transduction, the SARS-
CoV-2 Spike pseudotyped experiment was repeated ± ENZA
(Supplementary Fig. 3a–c) and qPCR and immunoblotting per-
formed to assess TMPRSS2 levels. As expected, TMPRSS2
expression was downregulated in response to the antiandrogen at
the RNA and protein level. To see if antiandrogens could inhibit
SARS-CoV-2 infection, TCID50 assays were performed with the
virus (Fig. 7b). For this, A549 cells were transfected with a vector
expressing ACE2 to facilitate the infection57, and treated with the
Fig. 3 TMPRSS2 is expressed at higher levels in the male lung compared
to female lung. The GTEx dataset40 was interrogated and expression of AR
and TMPRSS2 investigated in lung tissue and dichotomised by gender, M=
male (N= 220), F= female (N= 355). Box and whiskers: the centre line
represents the median, the box represents the 25th and 75th percentile and
the bars represent the min and max values. One-tailed t-test, *p=0.0403.
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antiandrogens for 72 h prior to infection. In agreement with the
pseudotyped virus experiments, the antiandrogens significantly
reduced SARS-CoV-2 viral titres by approximately 18-fold for
ENZA and 13-fold for BIC.
The data demonstrate that antiandrogens inhibit viral entry and
infection, and this is likely, at least in part, to be as a result of
downregulation of TMPRSS2. However, antiandrogens may also
regulate the expression of other factors important in viral entry.
Fig. 4 TMPRSS2 is androgen regulated in lung cell lines. A549, H1944 and BEAS-2B were incubated in hormone-depleted media for 72 h and treated with
±10 nM dihydrotestosterone (DHT) ± 10 μM enzalutamide (ENZA) for 24 h. RNA was harvested, reverse transcribed and qPCR performed to quantify
a TMPRSS2 and b FKBP5 expression. Mean of at least three independent repeats (±1 SEM). Significance determined using one-way ANOVA with Dunnett’s
multiple comparison test. TMPRSS2: A549 Vehicle Control (VC) v DHT p= 0.0190, DHT v ENZA p= 0.0228; H1944 VC v DHT p= 0.0410, DHT v ENZA
p= 0.0497. FKBP5: A549 VC v DHT p= 0.0250, DHT v ENZA p= 0.0493, DHT v DHT+ ENZA p= 0.0285; H1944 VC v DHT p= 5.7 × 10–6, DHT v
ENZA p= 7.1 × 10–5, DHT v DHT+ ENZA p= 1.7 × 10–5. c A549 were incubated in hormone-depleted media for 72 h and treated with ±10 nM DHT ±
10 μM ENZA for 24 h. Cells were lysed and proteins separated using SDS-PAGE. Immunoblotting was performed to visualise AR and TMPRSS2 expression
levels and β−actin used as a loading control. Densitometry was performed for AR and TMPRSS2, values normalised to β−actin and made relative to VC.
Representative immunoblots blots – A549 n= 3, H1944 n= 2. Source data are provided as a Source Data file.
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For example, it was recently demonstrated that antiandrogens can
also downregulate expression of ACE244. It is therefore possible that
the inhibitory effects of antiandrogens may be as a result of dual
downregulation of TMPRSS2 and ACE2. However, antiandrogens
were effective in the SARS-CoV-2 experiments, in cells with
exogenous ACE2 over-expressed from a promoter without the
endogenous regulatory regions so likely not subject to antiandrogen
regulation, supporting that the downregulation of TMPRSS2 plays a
pivotal role in the inhibitory effects of these antagonists.
The incomplete block of viral entry/infection could be a result
of S-protein priming via different proteases or due to alternative,
currently unknown, virus entry mechanisms. For example,
TMPRSS4 (not a known AR target gene) has also been shown
to facilitate SARS-CoV-2 cell entry in the lung58 and therefore
targeting additional proteases involved in S-priming may have
additive/synergistic effects.
Since the initial submission of this manuscript, several studies
investigating AR as a potential target for COVID-19 therapy have
been published. Contrary to the findings here, Li et al. did not
find TMPRSS2 to be androgen-regulated in lung cell lines55. This
may be due to the cell lines used in their study (H2126 and
H1437) differing to the lines used here. The group also found that
ENZA was unable to reduce SARS-CoV-2 infectivity in human
lung organoid models. Characterisation of the different cell types
present, and confirmation that the AR is functional in these
organoids, would assist in explaining the discrepancy between
these findings and our own. However, several other studies do
support the use of androgen signalling inhibitors as treatment
options for COVID-19. For example, Qiao et al. demonstrated
that androgens regulate TMPRSS2 expression in subsets of lung
epithelial cells44, while Deng et al. demonstrated that TMPRSS2 is
androgen-regulated in H460 lung cells, and that ENZA success-
fully reduces TMPRSS2 expression and blocks viral entry59.
Furthermore, Samuel et al. found that 5α-reductase inhibitors
(inhibitors of DHT synthesis) reduced TMPRSS2 (and ACE2)
expression and viral infection in lung organoids60.
Fig. 5 Enzalutamide downregulates Tmprss2 in mouse lung. a Relative expression of Ar, Tmprss2 and Ace2 mRNA from lung tissue of mice treated with
enzalutamide (ENZA, n= 9) or vehicle control (VC, n= 8) once daily for 3 days. Expression was normalised to housekeeping genes and made relative to
VC. Mean ± 1 SE. Student’s t-test (one-tailed) *p= 0.0367. b Example of Tmprss2 IHC in mouse lung. Representative immunostaining of epithelial cells (*)
and parenchyma/AT cells (#) in sections from n= 9 VC-treated mice, and n= 8 ENZA-treated mice. Bar= 50 μm c Log2 expression of Tmprss2, Ar and
Ace2 in lung tissue from male mice physically castrated (N= 3) vs intact male mice (N= 3) (GSE31341)50. Mean ± 1 SE. Student’s t-test (one-tailed), **p=
0.0018, *p= 0.0081. Source data are provided as a Source Data file.
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The data presented and literature discussed here suggest a role
for AR in regulation of TMPRSS2 in the lung, which may at least
in part explain why men with COVID-19 have a worse prognosis
compared to women. Data from prostate and breast tissue also
support regulation in other organs, which may also be targeted by
SARS-CoV-2. Importantly, our findings support the hypothesis
that therapies to target AR signalling could be used to
transcriptionally inhibit TMPRSS2 expression, in lung and other
organs. Furthermore, potential regulation of TMPRSS2 by other,
related receptors (revealed by cistromic analysis) opens up the
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Fig. 7 Antiandrogens reduce SARS-CoV-2 entry and infection in lung cells. a A549 cells were seeded in full media and treated with ±10 μM bicalutamide
(BIC) or enzalutamide (ENZA) for 72 h prior to transduction with SARS-CoV-2 Spike protein or VSV-G control pseudotyped lentiviral particles expressing
luciferase. Cells were left for an additional 48 h and luciferase assays performed. Luciferase data were normalised to total protein content. Mean of three
independent repeats ± 1 SE. One-way ANOVA with Sidak’s multiple comparison test. Vehicle Control (VC) v BIC p= 1.3 × 10−4, VC v ENZA p= 2.1 × 10−5.
b A549 were seeded in full media, transfected with ACE2 and treated with ±10 μM BIC or ENZA for 72 h prior to infection with SARS-CoV-2. Infectious
titres of SARS-CoV-2 in supernatants of A549-ACE2 were determined with TCID50 assays after 24 h of infection. n= 4, mean of two independent
experiments repeated in duplicate ± 1 SE. One-way ANOVA with Sidak’s multiple comparison test. VC v BIC p= 2.0 × 10−6, VC v ENZA p= 2.5 × 10−6.
c Schematic representation of how targeting the AR could reduce SARS-CoV-2 entry. Source data are provided as a Source Data file.
Fig. 6 Potential regulatory regions in the TMPRSS2 promoter. a ChIP-sequencing peaks of AR, FOXA1, GR and H3K27ac in LNCaP cells; FOXA1, GR and
H3K27ac in A549 lung cells; AR, H3K27ac, FOXA1, GR, ESR1 in MCF-7 breast cancer cells. The TMPRSS2 gene is highlighted in the purple shaded box and
the potential regulatory region 1 is boxed in yellow, the potential regulatory region 2 is boxed in orange. Potential AREs are marked in blue boxes
(MA0007.2) or green (determined by24). Position of potential MA0007.2 motifs around the TMPRSS2 gene separated into two regions, the first region
(regulatory region 1) covering areas of TSS and promoter/enhancers, the second region (regulatory region 2) covers more distant enhancer regions. b AR
motif MA0007.2 from JASPAR curated motif database. c ChIP-qPCR of AR binding, and IgG control, to AR-motif-containing sites within regulatory regions
1 and 2 in LNCaP, A549, and H1944 cells treated with 10 nM dihydrotestosterone (DHT) or vehicle control (VC) for 4 h. Data are normalised to input and
made relative to AR-IP VC. Data are the mean of three independent repeats. A maximum of one outlier was removed from each treatment using Grubbs’
test (alpha= 0.05). Source data are provided as a Source Data file.
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possibility of additional potential opportunities for pharmacolo-
gical inhibition of TMPRSS2 expression. Downregulation of
TMPRSS2 will result in attenuated spike protein priming,
reducing SARS-CoV-2 interaction with ACE2 and viral entry
(summarised in Fig. 7c). Antiandrogens are used routinely in, or
have been trialled for, the treatment of multiple diseases,
including prostate cancer, breast cancer, polycystic ovarian
syndrome and alopecia61. They have been shown to be well
tolerated in men and women61–63 and therefore antiandrogen
treatments should be considered as potential therapeutic, and
possibly preventative, strategies for COVID-19.
Methods
Ligands. Mibolerone was purchased from Perkin Elmer (Waltham, MA, USA) and
dissolved in ethanol. DHT/5alpha-Androstan-17beta-ol-3-one was purchased from
Sigma Aldrich (A8380) and dissolved in ethanol. ENZA was from Sigma Aldrich
(St. Louis, MO, USA) and was dissolved in DMSO.
Cell culture. A549, GMK (Vero E6), 293T, LNCaP, H1944 and BEAS-2B were
purchased from the ATCC (Manassas, VA, USA). A549 and 293T cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Aldrich), LNCaP
and H1944 in Roswell Park Memorial Institute (RPMI, Sigma Aldrich) medium
1640 supplemented with 10% FCS and 2mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin (PSG)64. BEAS-2B were grown in Bronchial Epithelial
Cell Growth Medium (Lonza, Basel, Switzerland). GMK were grown in DMEM
supplemented with 10% FCS, 1% non-essential amino acids (NEAA) and PS. For
experiments involving hormone manipulation, cells were incubated in phenol red
free DMEM or RPMI (Invitrogen, Carlsbad, CA, USA), supplemented with double
charcoal-stripped FCS and PSG (First Link UK Ltd., Wolverhampton, UK).
Immunoblotting. Cells were lysed in RIPA buffer (150 mM NaCl, 1% IGEPAL CA-
630, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris pH 7.4) containing freshly
added protease inhibitors (Halt Protease Cocktail, Thermo Fisher, Waltham, MA,
USA). Samples were incubated on ice for 10 min, sonicated 4 cycles of 30 s on/off
(Biorupter, Diagenode, Denville, NJ, USA) and centrifuged (21,100 ×g, 10 min,
4 °C). The DC protein assay (BioRad, Hercules, CA, USA) was used to quantify
protein concentrations. Then, 30 μg of protein was separated using SDS-PAGE and
immunoblotting performed65. Primary antibodies used were rabbit anti-TMPRSS2
(1:100, ab92323, Abcam, Cambridge, UK), mouse anti β-actin (1:8000, ab8226,
Abcam), rabbit anti-AR (1:2000, ab74272, Abcam) and mouse α-tubulin (1:10,000,
B-5-1-2, Sigma Aldrich). Secondary HRP-conjugated antibodies (Sigma Aldrich)
were used at 1:2000. Proteins were visualised using Immobilon Forte HRP substrate
(Merck Millipore, MA, USA) and a Fusion FX Chemi Imager (Vilber Lourmat,
Collégien, France).
Quantitative PCR analysis of gene expression in cell lines. Cells were seeded in
12-well plates and incubated with +10 nM DHT ± 10 μM BIC or ENZA for 6 or
24 h. RNA was extracted using Trizol (Thermo Fisher), following the manu-
facturer’s instructions. Then, 250 ng of RNA was reverse transcribed using a
LunaScript RT SuperMix Kit (NEB, Ipswich, MA, USA). Alterations in gene
expression were quantified using the Luna Universal qPCR Master Mix (NEB) and
a Roche 96 qPCR machine (Basel, Switzerland). TMPRSS2 data were normalised to
L19 data and the 2(–delta delta CT) method was used to calculate gene expression
changes. Primer sequences are provided in Supplementary Table 2.
Mouse studies. Ptenloxp/loxp;Pb-Cre4 mice (The Jackson Laboratory, Bar
Harbour, ME, USA), which have prostate-specific PTEN deletion66, were treated
with 50 mg/kg ENZA (in 5% DMSO+ 1% CMC+ 0.1% P80 oral gavage) or
vehicle control every day for 3 days. All work was carried out in accordance with
the provisions of the Animals (Scientific Procedures) Act 1986 of the United
Kingdom. The work was approved by Imperial College Animal Welfare and Ethical
Review Body and performed under an appropriate Home Office license
(PPL70_8705). Organs were snap frozen until RNA was extracted using a Monarch
RNA extraction kit (NEB) following disruption of frozen tissue utilising
mechanical disruption and enzymatic digestion with Proteinase K. Then, 2 μg of
RNA was reverse transcribed using Precision Nanoscript2 RT Kit (Primer Design,
Southampton, UK). Changes in gene expression were measured using SYBR Green
Fast Master Mix (Life Technologies, Carlsbad, CA, USA) and QuantStudio 7 Flex
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Gene
expression data were normalised to L19, Gapdh and Actb data and the 2(–delta delta
CT) method used to calculate changes in expression.
TMPRSS2 expression in tissue and cell line datasets. RNA-sequencing dataset
v8 was downloaded from the Genotype Tissue Expression (GTEx) Project Online
Portal67. Gene expression was normalised (inverse normal transformation) across
samples, and medians for AR and TMPRSS2 expression across each tissue were
calculated. Data from RNA sequencing of isolated single nuclei, performed on
surgical specimens of healthy, non-affected lung tissue from 12 lung adenocarci-
noma patients, were analysed for AR, TMPRSS2 and ACE2 expression using Eils
Lab UCSC Cell browser (https://eils-lung.cells.ucsc.edu)42. Sequencing data from
T47D cells treated with 10 nM DHT (GSE62243)39, and data from lungs of
castrated or intact mice (GSE31341)50 were log2 transformed. Two single-cell seq
datasets were investigated. The first dataset of lungs from 9 patients (GSE12296041)
was analysed using http://altanalyze.org/, and the second dataset of lungs from 12
donors42 was analysed using https://eils-lung.cells.ucsc.edu.
Identification of potential AREs. The AR binding motif, MA0007.2 was obtained
from the JASPAR online curated motif database54. Segments of DNA around the
TMPRSS2 gene were scanned for potential matches for presence of the MA0007.2
AR motif using FIMO68. Of the 40 possible MA0007.2 matches in regulatory
region 1 (p < 0.0001) and 34 possible matches in regulatory region 2 (p < 0.0001),
only response elements that correlated with binding peaks were selected.
Analysis of ChIP-sequencing data. ChIP-sequencing data (receptors in the pre-
sence of their cognate ligands) were analysed using Cistrome Analysis Pipeline and
visualised with WashU Epigenome Browser (v51.0.5). Datasets used: LNCaP – AR
(GSE94682)69, H3K27ac (GSE73783)70, FOXA1 (GSE94682)69 and NR3C1/GR
(GSE39880)71; A549 – H3K27ac (GSE29611)72, FOXA1 (GSE32465)73 and
NR3C1/GR (GSE91313)72; MC7 – AR (GSE104399)74, H3K27ac (GSE94804)75,
FOXA1 (GSE112969)76 and NR3C1/GR (GSE39879)71.
ChIP-qPCR. LNCaP, A549 and H1944 cells were grown in 15 cm plates to
approximately 80% confluency, before 4 h treatment with 10 nM DHT or vehicle
control. Cells were fixed with 4% formalin and ChIP performed77. Antibodies used
in overnight 4 °C immunoprecipitation were anti-AR (sc-7305, Santa Cruz Bio-
technology, Santa Cruz, CA, USA) and rabbit mouse IgG at 10 μg per sample. After
DNA isolation with phenol:chloroform:isoamyl alcohol and resuspension in water,
enrichment across the two potential TMPRSS2 regulatory regions was quantified
with qPCR (primers in Supplementary Table 2).
Immunohistochemistry. Lung samples from the above mouse studies were fixed in
4% formalin for 24 h, before transfer to 70% alcohol for storage before processing
into wax. Sections were probed with anti-Tmprss2 antibody (ab92323, Abcam) and
anti-AR (ab108341, Abcam) overnight at 4 °C at a 1:1000 dilution before detection
with the Histostain-Plus IHC HRP Kit and DAB (Thermo Fisher).
Quantification of cell entry using pseudotyped virus. SARS-CoV-2 Spike pro-
tein and VSV-G pseudotyped lentiviral particles expressing luciferase were pro-
duced in 293T cells cultured in a 6-well plate. For this, 1 µg pCAGGS (GAG/POL),
1.5 µg pCSFLW (Luciferase) and 1 µg pcDNA3.1-SARS2-Spike or pcDNA3.1-VSV-
G were transfected into 293T cells using FugeneHD (Promega, Madison, WI, USA)
at a ratio of 3 (lipid):1 (DNA) following the manufacturer’s instructions. The
lentiviral packaging constructs pCSFLW and pCAGGs-GAGPOL have been pre-
viously described78 and the codon-optimised pcDNA3.1-SARS2-Spike and
pcDNA3.1-VSV were kind gifts from Professor Robin Shattock (Imperial College
London)79 and Dr Nigel Temperton (University of Kent)80, respectively. After 5 h,
medium was changed and after another 72 h, the medium supernatant was har-
vested and centrifuged. The titre of lentiviral particles was measured with a HIV-1
Gag p24 ELISA (Bio-Techne, Minneapolis, MI, USA) according to the manu-
facturer’s protocol. A549 cells were grown in 48-well plates in full media with
±10 μM BIC or ENZA for 72 h prior to transduction with 3.75 × 104 TU per well.
Cells were left for an additional 48 h and viral entry quantified using luciferase
assay (E4030 Luciferase Assay System, Promega) according to the manufacturer’s
instructions. Luciferase activity was normalised to total protein content, quantified
using a NanoDrop UV Spectrophotometer (Thermo Fisher).
SARS-CoV-2 infection studies. A549 cells were seeded in 12-well plates and
transiently transfected with 1 μg of pCAGGS-ACE2 (synthesised by GeneArt,
Thermo Fisher) using Lipofectamine 3000 reagent as described by the manu-
facturer (Thermo Fisher). After 24 h, cells were treated with ±10 μM BIC or ENZA
for 56–72 h. Cells were then washed with PBS and infected with SARS-CoV-2. The
viral strain used was SARS-CoV-2/England/IC19/202 (IC19)79. All work involving
the use of SARS-CoV-2 was performed in a Containment Level 3 (CL3) laboratory
(St Mary’s, Imperial College London).
The virus was diluted in serum-free DMEM (supplemented with 1% NEAA and
PS) to a multiplicity of infection of 1. The inoculum was added to A549 cells
overexpressing ACE2 and incubated at 37 °C for 1 h. The inoculum was then
removed and cells maintained as described above. Twenty-four-hour post
infection, the culture supernatants were collected and quantified by TCID50 assay
on GMK Vero E6 cells11. Serial dilutions of the virus (in serum-free DMEM) were
added in 96-well plates and cells were left for 4–5 days before they were fixed with
2× crystal violet solution and analysed. TCID50 titres were determined by the
Spearman–Karber method81.
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Statistical analyses. Statistical analyses were performed using GraphPad PRISM
(v 6.0c). For experiments with two treatment arms, one-tailed t-tests were per-
formed. For analysis of more than two treatments, one-way or two-way ANOVA
was performed with Sidak’s, Dunnett’s or Tukey’s multiple comparison tests. For
comparison of AR and TMPRSS2 levels in the human lung (GTEx dataset), Wil-
coxon tests were performed. All experiments were at least three independent
repeats, unless otherwise stated.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
For analysis of TMPRSS2 in different tissues, the GTEx dataset was used (https://www.
gtexportal.org/home/). Transcriptomic analysis of gene expression was performed on datasets
obtained from GEO: T47D cells treated with 10 nM DHT (GSE62243); data from lungs of
castrated or intact mice (GSE31341). ChIP-Seq data were obtained from GEO: LNCaP – AR
(GSE94682), H3K27ac (GSE73783), FOXA1 (GSE94682) and NR3C1/GR (GSE39880); A549
– H3K27ac (GSE29611), FOXA1 (GSE32465) and NR3C1/GR (GSE91313); MC7 – AR
(GSE104399), H3K27ac (GSE94804), FOXA1 (GSE112969) and NR3C1/GR (GSE39879). sc-
Seq – AR, TMPRSS2 and ACE2 expression were analysed using Eils Lab UCSC Cell browser
(https://eils-lung.cells.ucsc.edu). Two additional single-cell datasets were investigated
(GSE122960). The remaining data are available within the article and the Supplementary
information. Source Data are provided with this paper.
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